Anemia Market: By Disease Type (Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, and Others), By Route of Administration (Oral and Injectable), By Product Type (Biologic and Non-Biologic), By End User (Hospital and Self-Administered) and By Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Anemia Market was valued at USD 7,832.8 million in 2022 and is anticipated to grow at a CAGR of 7.3% over 2023-2029. The anemia treatment market refers to the segment of the healthcare industry that focuses on developing and providing therapies, medications, and other interventions for the treatment of anemia. Anemia is a medical condition characterized by a deficiency in red blood cells or hemoglobin, which can lead to reduced oxygen-carrying capacity in the blood. This can result in symptoms such as fatigue, weakness, dizziness, and shortness of breath. The treatment of anemia aims to address the underlying cause of the condition and/or boost the production of red blood cells to restore normal hemoglobin levels.

The anemia treatment market includes various types of treatments, such as Iron supplements, Vitamin B12 supplements, Folate supplements, Erythropoiesis-stimulating agents (ESAs), and Blood transfusions to name a few. The market for anemia treatment is influenced by factors such as the prevalence of anemia, advancements in medical research and technology, healthcare infrastructure, and government healthcare policies. For instance, according to the World Health Organization, 30% (539 million) of non-pregnant women and 37% (32 million) of pregnant women aged 15–49 years were affected by anemia in 2019. Pharmaceutical companies, biotechnology firms, and medical device manufacturers are major players in this market, developing and marketing various treatments to meet the medical needs of patients with anemia. Moreover, Pharmaceutical companies develop and market drugs targeting anemia. For instance, Pharmacosmos launched Monoferric (Ferric Derisomaltose) for the treatment of iron deficiency anemia in adults.

Anemia Market Key Developments:
  • In February 2023, GlaxoSmithKline (GSK) received FDA Approval for its Jesduvroq (Daprodustat) indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months.
  • In November 2022, Sanofi received approval from the European Commission (EC) for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chronic autoimmune hemolytic anemia, where the body’s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as hemolysis.
  • In July 2021, Sandoz launched the generic version of Ferumoxytol, an intravenous medication used to treat iron deficiency anemia (IDA) in the United States.

Anemia Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.3%

Largest Market

North America

Fastest Growing Market

North America
Anemia Market Dynamics

Anemia, a prevalent blood disorder, showcases a dynamic market with significant growth drivers and promising opportunities. The rising global prevalence of anemia, attributed to factors like aging populations, malnutrition, and chronic diseases, acts as a primary growth driver. Additionally, increasing awareness among healthcare professionals and the general public regarding early detection and diagnosis of anemia boosts market demand for diagnostic tools and treatments. Technological advancements in medical devices and pharmaceuticals have opened new avenues for innovative anemia therapies, propelling market expansion. Furthermore, government initiatives and healthcare policies focusing on improving maternal and child health play a pivotal role in stimulating the market's growth potential. Moreover, the surge in research and development activities to develop more effective and accessible anemia treatments fuels opportunities for market players to cater to a growing patient base worldwide.

Key Features of the Reports

  • The anemia market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Anemia Market Segmentation

By Disease Type
  •  Iron Deficiency Anemia
  •  Chronic Kidney Disease Anemia
  •  Sickle Cell Anemia
  •  Aplastic Anemia
  •  Hemolytic Anemia
  •  Pernicious Anemia and Others
By Product Type
  • Biologic
  • Non-Biologic
By Route of Administration
  • Oral
  • Injectable
By End User
  • Hospitals
  • Self-Administered

Frequently Asked Questions

The Anemia market was valued at USD 7,832.9 million in 2022 and is expected to grow at 7.3% CAGR over the forecast period 2023 – 2029.

Key opportunities for the Anemia market include the potential for technological advancements in diagnostics and treatments, increasing focus on maternal and child health, and expanding research and development efforts to enhance therapeutic options.

Key trends in the Anemia market include the growing adoption of point-of-care diagnostic tools, the emergence of novel therapeutic approaches, increasing awareness about anemia management, and the integration of digital health solutions for better patient outcomes.

Sanofi, AbbVie Inc. (Allergan Plc), Pharmacosmos A/S, Covis Pharma GmbH, Pfizer Inc. (Global Blood Therapeutics, Inc.), GlaxoSmithKline plc, and Amgen Inc. are prominent companies operating in the field of Anemia market.

  • Sanofi
  • AbbVie Inc. (Allergan Plc)
  • Pharmacosmos A/S
  • Covis Pharma GmbH
  • Pfizer Inc. (Global Blood Therapeutics, Inc.)
  • GlaxoSmithKline plc
  • Amgen Inc
  • Biocon
  • Bluebird bio
  • Bayer AG
  • Eli Lilly
  • Acceleron Pharma

Adjacent Markets